phio pharmaceuticals - PHIO

PHIO

Close Chg Chg %
1.03 -0.03 -2.91%

Open Market

1.00

-0.03 (2.91%)

Volume: 30.70K

Last Updated:

Sep 10, 2026, 10:12 AM EDT

Company Overview: phio pharmaceuticals - PHIO

PHIO Key Data

Open

$1.03

Day Range

1.00 - 1.03

52 Week Range

0.81 - 4.19

Market Cap

$12.55M

Shares Outstanding

11.62M

Public Float

10.34M

Beta

0.80

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.34

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

196.69K

 

PHIO Performance

1 Week
 
-4.63%
 
1 Month
 
-5.50%
 
3 Months
 
-3.74%
 
1 Year
 
-52.75%
 
5 Years
 
-99.53%
 

PHIO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About phio pharmaceuticals - PHIO

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

PHIO At a Glance

Phio Pharmaceuticals Corp.
11 Apex Drive
Marlborough, Massachusetts 01752
Phone 1-508-767-3861 Revenue 0.00
Industry Biotechnology Net Income -8,698,000.00
Sector Health Technology Employees 6
Fiscal Year-end 12 / 2026
View SEC Filings

PHIO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 0.605
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 1.60
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

PHIO Efficiency

Revenue/Employee N/A
Income Per Employee -1,449,666.667
Receivables Turnover N/A
Total Asset Turnover N/A

PHIO Liquidity

Current Ratio 16.027
Quick Ratio 16.027
Cash Ratio 15.695

PHIO Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -63.897
Return on Equity -69.948
Return on Total Capital -43.173
Return on Invested Capital -69.948

PHIO Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Phio Pharmaceuticals - PHIO

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
193.00K 184.00K 35.00K 3.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
193.00K 184.00K 35.00K 3.00K
Depreciation
193.00K 184.00K 35.00K 3.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+0.52% -4.66% -80.98% -91.43%
Gross Income
(193.00K) (184.00K) (35.00K) (3.00K)
Gross Income Growth
-0.52% +4.66% +80.98% +91.43%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
11.27M 10.51M 7.35M 9.22M
Research & Development
7.01M 6.33M 3.64M 4.62M
Other SG&A
4.26M 4.18M 3.71M 4.60M
SGA Growth
-15.39% -6.70% -30.07% +25.37%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 126.00K
-
EBIT after Unusual Expense
(11.46M) (10.82M) (7.39M) (9.22M)
Non Operating Income/Expense
(18.00K) (2.00K) 237.00K 522.00K
Non-Operating Interest Income
- - 231.00K 520.00K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -100.00%
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(11.48M) (10.83M) (7.15M) (8.70M)
Pretax Income Growth
+13.60% +5.70% +33.96% -21.65%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
(2.29M) (2.55M) 2.21M (2.61M)
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
2.29M 2.55M (2.21M) 2.61M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(11.48M) (10.83M) (7.15M) (8.70M)
Minority Interest Expense
- - - -
-
Net Income
(11.48M) (10.83M) (7.15M) (8.70M)
Net Income Growth
+13.60% +5.70% +33.96% -21.65%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(11.48M) (10.83M) (7.15M) (8.70M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(11.48M) (10.83M) (7.15M) (8.70M)
EPS (Basic)
-90.9047 -46.763 -9.0798 -1.4535
EPS (Basic) Growth
+18.72% +48.56% +80.58% +83.99%
Basic Shares Outstanding
126.29K 231.51K 787.47K 5.98M
EPS (Diluted)
-90.9047 -46.763 -9.0798 -1.4535
EPS (Diluted) Growth
+18.72% +48.56% +80.58% +83.99%
Diluted Shares Outstanding
126.29K 231.51K 787.47K 5.98M
EBITDA
(11.27M) (10.51M) (7.35M) (9.22M)
EBITDA Growth
+15.39% +6.70% +30.07% -25.37%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 14.00
Number of Ratings 1 Current Quarters Estimate -0.36
FY Report Date 09 / 2026 Current Year's Estimate -1.445
Last Quarter’s Earnings -0.36 Median PE on CY Estimate N/A
Year Ago Earnings -1.45 Next Fiscal Year Estimate -0.61
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate -0.36 -0.39 -1.45 -0.61
High Estimates -0.35 -0.37 -1.42 -0.45
Low Estimate -0.37 -0.40 -1.47 -0.77
Coefficient of Variance -3.93 -5.51 -2.45 -37.09

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Phio Pharmaceuticals - PHIO

Date Name Shares Transaction Value
Aug 20, 2026 Robert J. Bitterman Chairman, Pres. & CEO; Director 431,421 Open market or private purchase of non-derivative security Non-derivative transaction at $1.06 per share 457,306.26
Sep 16, 2025 Robert L. Ferrara Director 38,766 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Phio Pharmaceuticals in the News